ArticleJournal of virology1998
A replication-competent retrovirus arising from a split-function packaging cell line was generated by recombination events between the vector, one of the packaging constructs, and endogenous retroviral sequences.
Article in Journal of virology, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 101 citations in OpenAlex.
- Risks of replication-competent retro/lentivirus from associated vector systems: Is it time for a roadmap toward reduced testing?Molecular therapy. Methods & clinical development · 2025Review
- Meeting FDA Guidance recommendations for replication-competent virus and insertional oncogenesis testing.Molecular therapy. Methods & clinical development · 2023Review
- Rapid Lentiviral Vector Producer Cell Line Generation Using a Single DNA Construct.Molecular therapy. Methods & clinical development · 2020Article
- Expression Analysis of GDNF/RET Signaling Pathway in Human AD-MSCs Grown in HEK 293 Conditioned Medium (HEK293-CM).Cell biochemistry and biophysics · 2020Article
- Screening Clinical Cell Products for Replication Competent Retrovirus: The National Gene Vector Biorepository Experience.Molecular therapy. Methods & clinical development · 2018Article
- Absence of Replication-Competent Lentivirus in the Clinic: Analysis of Infused T Cell Products.Molecular therapy : the journal of the American Society of Gene Therapy · 2018Article
- Review
- Article
- Alpharetroviral vectors: from a cancer-causing agent to a useful tool for human gene therapy.Viruses · 2014Review
- A Rev-Independent gag/pol Eliminates Detectable psi-gag Recombination in Lentiviral Vectors.BioResearch open access · 2013Article
- A reporter system for replication-competent gammaretroviruses: the inGluc-MLV-DERSE assay.Gene therapy · 2013Article
- Abrogated cryptic activation of lentiviral transfer vectors.Scientific reports · 2012Article
- Replication-competent lentivirus analysis of clinical grade vector products.Molecular therapy : the journal of the American Society of Gene Therapy · 2011Article
- Cross-packaging of genetically distinct mouse and primate retroviral RNAs.Retrovirology · 2009Article
- Design of a trans protease lentiviral packaging system that produces high titer virus.Retrovirology · 2007Article
- Retroviral vector production in the National Gene Vector Laboratory at Indiana University.Gene therapy · 2005Review
- The use of retroviral vectors for gene therapy-what are the risks? A review of retroviral pathogenesis and its relevance to retroviral vector-mediated gene delivery.Genetic vaccines and therapy · 2004Article
- Kinetics and characteristics of replication-competent revertants derived from self-inactivating foamy virus vectors.Gene therapy · 2004Article
- Human primary T lymphocytes have a low capacity to amplify MLV-based amphotropic RCR and the virions produced are largely noninfectious.Gene therapy · 2003Article
- Construction of a retroviral vector production system with the minimum possibility of a homologous recombination.Gene therapy · 2003Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previously we reported the presence of a replication-competent retrovirus in supernatant from a vector-producing line derived from a widely used split-function amphotropic packaging cell line. Rigorous routine screening of all retroviral stocks produced in our laboratory has not, previously or since, indicated the presence of such a virus. Replication-competent retroviruses have never previously been used in our laboratory, and stringent screening of all routinely used cell lines has not revealed the presence of any helper viruses. Therefore, it is highly unlikely that this virus represents an adventitious cross-contaminant or had been imported unknowingly with our cell line stocks. PCR studies with DNA from infected cell lines and Northern blot analysis and reverse transcriptase PCR with RNA from infected cells suggest that the helper virus arose by recombination events, at sites of partial homology, between sequences in the vector, one of the packaging constructs, and endogenous retroviral elements. These recombinations were not present in stocks of the packaging cell line or in an initial stock of the vector-producing line, indicating that these events occurred while the vector-producing line was being passaged for harvest of supernatant stocks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.